• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

MElanoma Research Lymph Node Prediction Implementation National_001

Study Purpose

MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Newly diagnosed patients with invasive malignant melanoma of the skin (AJCC 8th edition staging guidelines) elected to undergo sentinel lymph node biopsy per the treating physician's recommendation.
  • - Male or female, age ≥18 years.

Exclusion Criteria:

  • - Full primary melanoma pathology report unavailable.
  • - Documented clinically apparent nodal metastases at diagnosis.
  • - Distant metastatic disease (M1a,b,c,d) clinically present at primary diagnosis.
  • - Any prior or concurrent primary invasive melanoma mapping to the same draining lymph node basin(s).
  • - Documented history of another (prior or concurrent) primary invasive melanoma of T1b or greater at any site within the last 5 years.
  • - Previous surgery in or radiation therapy to the draining lymph node basin(s) of the current primary melanoma.
  • - Ocular, vulvar, perianal or mucosal melanomas or melanocytic tumors of uncertain malignant potential (MELTUMP) or atypical Spitz tumors.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04759781
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

SkylineDx
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Vernon K. Sondak, MDTina J. Hieken, MDMichael E. Egger, MD, MPH
Principal Investigator Affiliation Moffitt Cancer CenterMayo ClinicUniversity of Louisville
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Melanoma

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Moffitt Cancer Center, Tampa, Florida

Status

Address

Moffitt Cancer Center

Tampa, Florida, 33612

Emory University School of Medicine, Atlanta, Georgia

Status

Address

Emory University School of Medicine

Atlanta, Georgia, 30322

University of Kentucky, Lexington, Kentucky

Status

Address

University of Kentucky

Lexington, Kentucky, 40506

University of Louisville, Louisville, Kentucky

Status

Address

University of Louisville

Louisville, Kentucky, 40292

University of Michigan, Ann Arbor, Michigan

Status

Address

University of Michigan

Ann Arbor, Michigan, 48109

Mayo Clinic, Rochester, Minnesota

Status

Address

Mayo Clinic

Rochester, Minnesota, 55905

Memorial Sloan Kettering Cancer Center, New York, New York

Status

Address

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Duke University, Durham, North Carolina

Status

Address

Duke University

Durham, North Carolina, 27705

Huntsman Cancer Institute, Salt Lake City, Utah

Status

Address

Huntsman Cancer Institute

Salt Lake City, Utah, 84112

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact